GlassScriptPhysician profile
Ruth M Human
NPI 1891292686
$7,921.17
in general payments reported to CMS, 2019-2025
50 companies · $2,229 in 2025
The $2,229 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $483 · 2022: $1,634 · 2023: $1,751 · 2024: $1,825 · 2025: $2,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,804.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,587.40 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,351.86 | 2021-2025 | Airsupra, Farxiga, Wainua |
| Lilly USA, LLC | $625.85 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $574.58 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $489.91 | 2021-2025 | |
| Pfizer INC. | $401.44 | 2021-2025 | |
| Glaxosmithkline, LLC. | $311.93 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $198.12 | 2022-2025 | Rexulti, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $184.28 | 2022-2025 | Caplyta |
| Amgen INC. | $181.81 | 2021-2023 | Prolia, Evenity |
| Medtronic, INC. | $156.30 | 2022-2025 | Intellis Adaptivestim |
| Exact Sciences Corporation | $154.58 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.46 | 2021-2025 | Ofev, Jardiance |
| Novartis Pharmaceuticals Corporation | $132.43 | 2023-2024 | |
| Axsome Therapeutics, INC. | $125.25 | 2022-2025 | Auvelity |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Human listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.